^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Colon Cancer
    Drug:capecitabine (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Published date:
    02/22/2019
    Excerpt:
    XELODA (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for...Adjuvant Colon Cancer...Patients with Dukes’ C colon cancer.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    07/20/2020
    Excerpt:
    Recommendations: For patients not fit for or not tolerating oxaliplatin, either capecitabine or LV5FU2 (de Gramont) infusion is acceptable adjuvant regimens for a 6-month duration [I, A].
    DOI:
    10.1016/j.annonc.2020.06.022
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NICE
    Title:

    Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer

    Published date:
    04/26/2006
    Excerpt:
    The following are recommended as options for the adjuvant treatment of patients with stage III (Dukes' C) colon cancer following surgery for the condition:...capecitabine as monotherapy